Allergic Fungal Rhinosinusitis Clinical Management: From Clinic to Operating Room

Sunday, September 29, 2024

8:00 AM – 9:00 AM EDT

Location: MBCC, Art Deco 229AB

CME/MOC Credit: 1

Disclosure(s):

Corinna G. Levine, MD, MPH:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Roy R. Casiano, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Amber U. Luong, MD, PhD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: Allergic Fungal Rhinosinustis (AFRS) is a severe subtype of Chronic Rhinosinusitis with nasal polyps characterized by thick eosinophilic mucin containing fungal hyphae. Practitioners face several challenges treating AFRS:
- Heterogeneous clinical presentation
- Rapid recurrence in mucin and polyps in >50% of patients
- Frequent advanced disease at presentation with bony erosion/destruction
- Mass effect on the orbit or intracranial space, which can cause erroneous concern for tumors when improperly imaged
Additionally the impact of Social Determinants of Health have an important role in this disease. The panelists have published and unpublished data that indicates that this disease disproportionately impacts racial and ethnic minorities and those of lower socioeconomic status.
This panel will guide practitioners through these challenges to perform appropriate work-up and how to develop a multi-provide the best clinical management for AFRS.

Goals: The panel will build on last years presentation by providing an overview of the updates in our understanding of AFRS including high-risk populations and geographic locations. We will briefly review the challenges with the classic diagnostic criteria and appropriate work up for AFRS and AFRS-like variants. The panel will place particular emphasis on an interactive discussion of the clinical management of AFRS using case examples. Through the cases we will review how to determine the timing of medical, surgical, and adjunctive treatments and discussion of potential complications. We will also discuss new published and unpublished data on AFRS clinical management and health disparities.

Target Audience: This panel is designed for a general otolaryngology audience in order to give a comprehensive overview of our current AFRS knowledge and review the options for the best clinical practice management.

Learning Objectives:

Discuss updates in the pathophysiology, epidemiology, diagnosis and medical treatment of Allergic Fungal Rhinosinusitis (AFRS).
Review cases to highlight standard and cutting-edge medical and allergy treatment options and discuss the timing of in office procedures and surgical intervention for AFRS.
Discuss new clinical research and how it impacts clinical care for AFRS.

Moderator(s)

Corinna G. Levine, MD, MPH

Associate Professor, Rhinology + Skull Base Surgery
University of Miami, Otolaryngology
Miami, Florida, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Panelist(s)

Corinna G. Levine, MD, MPH

Associate Professor, Rhinology + Skull Base Surgery
University of Miami, Otolaryngology
Miami, Florida, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
AH

Ashleigh Halderman, MD

United States

Disclosure information not submitted.
RC

Roy R. Casiano, MD

Professor of Otolaryngology; Director: Rhinology and Endoscopic Skull Base Program
University of Miami Miller School of Medicine
Miami, FL, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
AL

Amber U. Luong, MD, PhD

Professor of Otolaryngology, Vice Chair of Academic Affairs
University of Texas Houston, McGovern Medical School
Houston, TX, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.